Page last updated: 2024-12-08

n-butylpyridinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID12184310
SCHEMBL ID1358752
MeSH IDM0134379

Synonyms (18)

Synonym
n-butylpyridinium
AKOS005145867
1-butylpyridinium bis(trifluoromethanesulfonyl)amide
SCHEMBL1358752
1-butylpyridinium bis(trifluoromethylsulfonyl)imide
mfcd16038143
187863-42-9
n-butylpyridinium bis((trifluoromethyl)sulfonyl)imide
n-butylpyridinium bis(trifluoromethylsulfonyl)imide
1-butylpyridinium bis(trifluoromethanesulfonyl)imide
B5571
BS-44779
bis(trifluoromethylsulfonyl)azanide;1-butylpyridin-1-ium
D89147
CS-0187723
1-butylpyridiniumbis(trifluoromethanesulfonyl)imide
SY234389
1-butylpyridiniumbis(trifluoromethanesulfonyl)amide

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"3 h, and the bioavailability was determined to be 47% at 6 h based on the blood toxicokinetics and 67% at 72 h based on urinary excretion."( Characterization of the disposition and toxicokinetics of N-butylpyridinium chloride in male F-344 rats and female B6C3F1 mice and its transport by organic cation transporter 2.
Cheng, Y; Hooth, MJ; Sipes, IG; Wright, SH, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" The influence of catalyst dosage and pH solution on ionic liquid degradation was analysed, achieving almost total oxidation after 60 min under optimal conditions (2 g/L catalyst concentration and pH 3)."( Heterogeneous electro-Fenton catalyst for 1-butylpyridinium chloride degradation.
Meijide, J; Pazos, M; Sanromán, MÁ, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.69)18.7374
1990's0 (0.00)18.2507
2000's5 (38.46)29.6817
2010's5 (38.46)24.3611
2020's2 (15.38)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]